Gilead Sciences: Hepatitis trials

The registry lists 25 Hepatitis studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 19 have results posted.

Phase 1 3Phase 2 10Phase 3 9Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated CirrhosisCompletedNCT02996682Phase 3Results posted
• Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)CompletedNCT02836249Phase 3Results posted
• Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)CompletedNCT02836236Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being TreatedCompletedNCT02579382Phase 2Results posted
• Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e AntigenCompletedNCT01940471Phase 3Results posted
• Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e AntigenCompletedNCT01940341Phase 3Results posted
• Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV InfectionCompletedNCT01909804Phase 2Results posted
• Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV InfectionCompletedNCT01858766Phase 2Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)CompletedNCT01851330Phase 3Results posted
• Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) InfectionCompletedNCT01838590Phase 3Results posted
• Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3CompletedNCT01808248Phase 2Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV InfectionCompletedNCT01768286Phase 3Results posted
• Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver FibrosisCompletedNCT01707472Phase 2Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCVCompletedNCT01701401Phase 3Results posted
• Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-TransplantCompletedNCT01559844Phase 2Results posted
• Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3CompletedNCT01260350Phase 2Results posted
• Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected PatientsCompletedNCT01188772Phase 2Results posted
• A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B InfectionCompletedNCT00736190Phase 4Results posted
• Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.CompletedNCT00298363Phase 2Results posted
• Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis CApproved for marketingNCT01779518
• A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis CCompletedNCT01591668Phase 1
• A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus InfectionCompletedNCT01590654Phase 1
• A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis BCompletedNCT01590641Phase 1
• Registry Study for Patients With Chronic HBV Receiving Nucleotide TherapyCompletedNCT01590615
• Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus InfectionTerminatedNCT00874796Phase 2